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Effects of exenatide twice daily versus sitagliptin
on 24-h glucose, glucoregulatory and hormonal
measures: a randomized, double-blind, crossover study
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2Lilly USA, LLC, Indianapolis, IN, USA
Aim: To compare exenatide and sitagliptin glucose and glucoregulatory measures in subjects with type 2 diabetes.
Methods: An 8-week, double-blind, randomized, crossover, single-centre study. Eighty-six subjects (58% female, body mass index 35 ±
5k g / m 2, haemoglobin A1c 8.3 ± 1.0%) received either exenatide 10 μg (subcutaneous) twice daily or sitagliptin 100 mg (oral) daily for
4 weeks and crossed to the other therapy for an additional 4 weeks. Main outcome was time-averaged glucose during the 24-h inpatient visits.
Results: Both treatments decreased average 24-h glucose, but exenatide had a greater effect [between-group difference: −0.67 mmol/l, 95%
conﬁdence interval (CI): −0.9 to −0.4 mmol/l]. Both treatments decreased 2-h postprandial glucose (PPG), area under the curve of glucose
above 7.8 mmol/l (140 mg/dl) and 11 mmol/l (200 mg/dl) and increased the time spent with glucose between 3.9 and 7.8 mmol/l (70 and
140 mg/dl) during 24 h, but exenatide had a signiﬁcantly greater effect (p < 0.05). Both treatments decreased postprandial serum glucagon,
with exenatide having a greater effect (p < 0.005). Both treatments decreased fasting blood glucose to a similar degree (p = 0.766). Sitagliptin
increased, while exenatide decreased, postprandial intact glucagon-like peptide-1. Both drugs improved homeostasis model assessment of
β-cell function (HOMA-B), with exenatide having a signiﬁcantly greater effect (p = 0.005). Both exenatide and sitagliptin decreased 24-h
caloric intake, with exenatide having a greater effect (p < 0.001). There was no episode of major hypoglycaemia. Adverse events were mild
to moderate and mostly gastrointestinal in nature with exenatide. No study withdrawals were due to an adverse event.
Conclusion: Compared to sitagliptin, exenatide showed signiﬁcantly lower average 24-h glucose, 2-h PPG, glucagon, caloric intake and
improved HOMA-B.
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Introduction
Advancesinthetreatmentofhyperglycaemiaincludeglucagon-
likepeptide-1(GLP-1)receptoragonists,suchasexenatideand
liraglutide,anddipeptidylpeptidase-4(DPP-4)inhibitors,such
as sitagliptin and saxagliptin. Exenatide binds and activates the
GLP-1 receptor, while sitagliptin increases endogenous GLP-1
concentrations by inhibiting DPP-4 degradation of circulating
GLP-1 [1,2]. Exenatide stimulates glucose-dependent insulin
secretion, suppresses inappropriately high glucagon secretion,
slows gastric emptying and reduces food intake [3–7].
Sitagliptin enhances glucose-dependent insulin secretion and
decreasesglucagonsecretionwithnosigniﬁcanteffectongastric
emptying or food intake [8,9].
A recent clinical study by DeFronzo et al. [10] comparing
the acute effects of exenatide twice daily (BID) and sitagliptin
reported that exenatide produced a greater decrease in 2-h
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postprandial glucose (PPG) than sitagliptin. The primary
objective of the current study was to examine glucose proﬁles
over an entire 24-h period in subjects treated with exenatide
or sitagliptin and to compare their mechanisms of action using
different measures of glycaemic control, β-cell function, α-cell
function and 24-h caloric intake.
Methods
Experimental Design
This was an 8-week, 2-arm, 2-period crossover, double-
blind, double-dummy, randomized, active comparator trial.
The study was approved by the institutional review board
at one site in the USA that enrolled patients with type 2
diabetes into the study from 2008 to 2009. Inclusion criteria
were age 18–70 years, body mass index (BMI) 25–45 kg/m2,
stable body weight for at least 3 months prior to screening
visit, haemoglobin A1c (HbA1c) ≥7% and ≤11%, fasting
glucose <280 mg/dl and subjects must have been on a
stable dose of metformin or thiazolidinedione for at least
60 or 120 days, respectively. Exclusion criteria were females of
childbearing potential; treatment with insulin, exenatide (orDIABETES, OBESITY AND METABOLISM original article
any GLP-1 receptor agonist), sulphonylureas, drugs affecting
gastrointestinal motility, weight loss drugs, corticosteroids,
α-glucosidase inhibitors; history of organ transplant; history
of liver or renal disease; fasting triglycerides >400 mg/dl;
blood pressure >165/90 mm Hg. All subjects provided written
informed consent prior to undergoing any study procedure
or receiving any study treatment. The study was performed
in accordance with the principles of the Declaration of
Helsinki [11] and all regulatory requirements.
At the baseline and subsequent two inpatient stays,
subjects were admitted during late afternoon (17:00 hours)
for 24 h. Following the baseline visit, all subjects began self-
administering study treatments at home. All subjects received
a capsule once daily in the morning (sitagliptin 100 mg or
placebo)andtwoinjections[exenatide5 μg(1st week)to10 μg
(additional 3 weeks), or placebo] in addition to their prestudy
medication(s). At the end of the ﬁrst 4 weeks, subjects were
switched to the alternative treatment. Subjects received their
injections and a capsule before the breakfast test meal during
the postrandomization 24-h inpatient visits.
Theprimaryefﬁcacymeasurewasthetime-averagedglucose
duringthe24-hinpatientvisits [12].The24-hmeanglucosewas
calculatedfrom36glucosemeasurementsover24 h.Additional
efﬁcacy measures were fasting glucose (08:00 hours); 2-h PPG
(from start of breakfast meal); difference between minimum
and maximum glucose concentrations during 24 h calculated
from highest glucose value to lowest glucose value; area
under the curve (AUC) of glucose above 7.8 mmol/l [AUC
> 7.8 mmol/l (140 mg/dl)] and above 11 mmol/l [AUC >
11 mmol/l (200 mg/dl)] calculated by the trapezoid method,
using area above 7.8 or 11 mmol/l, respectively. The WHO
criteria for the diagnosis of diabetes and impaired glucose
tolerance,aswellaspreviouswork [12],wereconsiderationsin
the choice of these arbitrary values to put the hyperglycaemic
exposure into a clinical context; proportion of time during
24 h with a glucose 3.9–7.8 mmol/l; and homeostasis model
assessment of β-cell function (HOMA-B), calculated using
the updated HOMA model [13]. Safety data collected
included hypoglycaemic and other adverse events. Minor
hypoglycaemiawasdeﬁnedasself-reportedtransientsymptoms
of hypoglycaemia and a blood glucose <3 mmol (54 mg/dl).
Major hypoglycaemia was deﬁned as any episode consistent
with hypoglycaemia resulting in the loss of consciousness or
seizure or documented hypoglycaemia <3 mmol (54 mg/dl)
requiring assistance. All efﬁcacy and safety measures were
predeﬁned in the study protocol. Because of the short duration
of this study, HbA1c was measured only at baseline.
Individualized Meal and Caloric Intake Measurements
During the 24-h inpatient visits, three similar caloric and
macronutrient content meals were given, beginning with
the evening meal. All meals were individualized for each
subject based on gender and weight [10,12]. The mixed
test meal (breakfast) provided approximately 7 kcal/kg (55%
carbohydrate, 15% protein and 30% fat). Subjects were
encouraged to consume the entire breakfast meal within
15 min. Any calories not consumed were carried over to the
midday meal. Subjects had no time restriction for the midday
or evening meals. Food intake was recorded by weighing the
food not consumed at each meal.
Statistical Analyses
Statistical analyses were performed using SAS version 9.1.
All analyses were based on two-sided tests at the 0.05 α
level. To account for multiplicity, p-values for postbreakfast
serial measurements were reported only if <0.005 (0.05/10)
instead of <0.05, as there were 10 or fewer values for each
measurement.Baselinecharacteristicsweredescribedbymean,
standard deviation (SD) or n (%) and postbaseline efﬁcacy
values were described by least-squares (LS) mean and standard
error (SE).
Analysis of efﬁcacy variables and hypoglycaemia included
all subjects who received at least one dose of study medication
and completed the ﬁrst treatment period. Baseline for both
treatment periods was deﬁned as the randomization visit.
Adverse events were analyzed on all randomized subjects.
Analyses for continuous variables used Grizzle’s model [14],
including effects for treatment, period, sequence, baseline of
the variable analyzed and baseline HbA1c stratum (<8.5%,
≥8.5%),withsubjectasarandomeffect.Assumingatreatment
differenceof0.5 mmol/landawithin-patientSDof1.1 mmol/l,
58 completing subjects would provide 90% power to detect
a signiﬁcant difference between the average 24-h glucose
concentrations during treatment with exenatide or sitagliptin.
Results
Subject Characteristics
Eighty-six subjects were randomized but three subjects
discontinued before receiving the study drug. Of those 83
subjects, 82 were receiving metformin and 1 was receiving
thiazolidinedione (ﬁgure 1). The treatment sequences were
exenatide/sitagliptin n = 41 and sitagliptin/exenatide n = 42
(ﬁgure 1). Baseline characteristics are shown in Table 1.
24-Hour Glucose Proﬁles
At baseline, the 24-h glucose proﬁles were similar between
treatment groups (ﬁgure 2A). After 4 weeks, both treatments
showed a signiﬁcant (p < 0.001) reduction from baseline
in the average 24-h glucose. Exenatide treatment led to a
greater reduction (p < 0.001) than sitagliptin from baseline
in average glucose concentration [between-group difference:
−0.67 mmol/l, 95% CI: −0.9, −0.4 mmol/l] over 24 h (ﬁgure
2B, Table 2).
Both exenatide and sitagliptin signiﬁcantly (p < 0.001)
reduced fasting glucose and mean 2-h PPG from baseline
(Table 2). A signiﬁcant (p < 0.001) treatment difference,
favouring exenatide, was shown at endpoint for the 2-h
PPG [−3.5 mmol/l, 95% CI (−4.2, −2.9 mmol/l)] but not for
fastingglucose(Table 2).Thedifferencebetweentheminimum
and maximum glucose values during the 24-h inpatient visit
signiﬁcantly (p < 0.001) decreased in both treatment groups
with a treatment difference (p = 0.01) favouring exenatide
(Table 2).
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3 subjects received no 
study drug 
73 screen failures 
Screening (visit=1, treatment week=-1) 
159 patients entered
Exenatide/Sitagliptin 
(5 subjects discontinued during 
period 2) 
1 protocol violation 
2 subject decision  
1 lost to follow-up 
1 sponsor decision
Sitagliptin/Exenatide 
(4 subjects discontinued during 
period 2) 
1 protocol violation 
2 subject decision  
1 sponsor decision 
64 Subjects completed 
Treatment period 2 (visit=3-4, week=4-8) 
Exenatide BID + Placebo Sitagliptin 
(5µg EXE BID 1 week, 10µg EXE BID 3 week) 
33 Subjects 
Treatment period 2 (visit=3-4, week=4-8) 
Sitagliptin + Placebo Exenatide 
(100mg Si 4 week) 
31 Subjects 
83 subjects randomly assigned to study drug and took at least one dose 
Randomization (visit=2, treatment week=0) 
86 subjects randomly assigned to study drug 
Treatment period 1 (visit=2-3, week=1-4) 
Exenatide BID + Placebo Sitagliptin 
(5µg EXE BID 1 week, 10 µg EXE BID 3 week) 
41 Subjects 
Treatment period 1(visit=2-3, week=1-4) 
Sitagliptin + Placebo Exenatide 
(100mg Si 4 week) 
42 Subjects 
Exenatide/Sitagliptin 
(5 subjects discontinued during 
period 1) 
2 protocol violation 
2 subject decision  
1 lost to follow-up 
Sitagliptin/Exenatide 
(5 subjects discontinued during 
period 1) 
1 protocol violation 
2 subject decision  
1 sponsor decision 
1 physician decision 
Figure 1. Study design and subject disposition. Subjects were to inject
5 μg (BID, before morning and evening meals) of exenatide during the
ﬁrst week of the treatment period. Thereafter, subjects were to inject 10 μg
(BID, before morning and evening meals) of exenatide for the remainder
of the treatment period. Placebo exenatide was administered in the same
manner.Subjectswerefurtherrandomizedtoadministertheirexenatideor
placebo injection either within 15 min before meals or 45–60 min before
meals. Subjects continued to administer injections at their speciﬁed time
throughoutthestudyexcept duringthe24-h assessments. BID,twicedaily;
EXE, exenatide; QAM, once daily in the AM; Si, sitagliptin.
At endpoint, both treatments signiﬁcantly (p < 0.001)
decreasedtheaverageexposuretohyperglycaemiaasmeasured
by AUC for glucose values above 7.8 mmol/l and above
11 mmol/l, with a signiﬁcant (p ≤ 0.01) treatment difference
favouring exenatide (ﬁgure 2C and D, Table 2). Compared
with baseline, both exenatide and sitagliptin signiﬁcantly (p <
0.001) increased the time spent with glucose values between
3.9 and 7.8 mmol/l with a signiﬁcant (p < 0.001) treatment
difference favouring exenatide at endpoint (Table 2).
Breakfast Test Meal
At endpoint, the PPG concentrations were signiﬁcantly
lower (p < 0.005) with exenatide compared to sitagliptin
at most time points following the test meal (ﬁgure 3A).
Postprandial insulin concentrations with exenatide were lower
at some points than with sitagliptin (ﬁgure 3B). At endpoint,
postprandial concentrations of intact GLP-1 signiﬁcantly
increased over baseline with sitagliptin, but decreased with
exenatide (ﬁgure 3C). While both exenatide and sitagliptin
signiﬁcantly (p < 0.005) decreased glucagon concentrations at
most points after the breakfast meal, exenatide had a greater
Table 1. Subject demographics and baseline characteristics for exe-
natide/sitagliptin and sitagliptin/exenatide sequences.
Exenatide/
sitagliptin
sequence
(n = 41)
Sitagliptin/
exenatide
sequence
(n = 42) Overall
Age (years) 55 ± 10 54 ± 95 4 ± 10
Sex: females, n (%) 19 (46) 29 (69) 48 (58)
R a c e ,n( % )
American
Indian/Native
American
1 (2) 0 (0) 1 (1)
Black/African
American
2 (5) 3 (7) 5 (6)
Caucasian 38 (93) 39 (93) 77 (93)
Ethnicity, n (%)
Hispanic or Latino 25 (61) 30 (71) 55 (66)
Non-Hispanic or
Latino
16 (39) 12 (29) 28 (34)
Body weight (kg) 98.2 ± 22.5 94.0 ± 20.3 96.1 ± 21.4
Height (cm) 166.6 ± 10.6 163.7 ± 10.3 165.2 ± 10.5
BMI (kg/m2) 35.0 ± 5.5 34.9 ± 5.5 34.9 ± 5.5
Duration of diabetes
(years)
7 ± 68 ± 77 ± 7
HbA1c (%) 8.3 ± 1.0 8.3 ± 1.1 8.3 ± 1.0
Fasting TG (mmol/l) 2.1 ± 1.0 3.4 ± 8.2 2.8 ± 5.9
BMI, body mass index; HbA1c, haemoglobin A1c; n, number of subjects;
TG, triglycerides.
effect (p < 0.005; ﬁgure 3D). Figure 4A and B show the 24-h
average glucose and the 2-h PPG at baseline, end of treatment
period 1 and end of treatment period 2 by treatment sequence.
Thetestforsequence(whichcanindicateacarryovereffect)on
the 24-h average glucose was not signiﬁcant (p = 0.056).
β-Cell Function
Both exenatide and sitagliptin signiﬁcantly (p < 0.001)
increased HOMA-B, with exenatide having a greater effect
(p = 0.005, Table 2). At endpoint, fasting insulin levels were
signiﬁcantly higher in exenatide versus sitagliptin (135 vs.
105 pmol/l, respectively).
Effect on Food Consumption
At baseline, the 24-h caloric intake (LS mean ± SE) was similar
between treatment sequences (exenatide: 1968 ± 41 kcals;
sitagliptin: 1952 ± 41 kcals). At endpoint, the caloric intake
was signiﬁcantly lower (p < 0.001) over 24 h in both groups,
with exenatide having a greater effect (1745 ± 35 vs. 1853 ± 35
kcals; p < 0.001, respectively). At endpoint, the calorie intake
was not signiﬁcantly different between groups at the morning
(exenatide 541 ± 15; sitagliptin 543 ± 15) or evening meal
(exenatide 682 ± 17 kcals; sitagliptin 697 ± 17 kcals). Calories
consumed were signiﬁcantly less (p < 0.001) with exenatide
compared to sitagliptin at the midday meal (exenatide 531 ±
18 kcals; sitagliptin 612 ± 18 kcals).
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Figure 2. Metabolic parameters. (A) 24-h glucose proﬁle at baseline; (B) 24-h glucose proﬁle at endpoint; (C) AUC for glucose values above 7.8 mmol/l
and (D) AUC for glucose values above 11 mmol/l. AUC, area under the curve.
Effect on Weight
Both treatments led to decreases in weight (−1.37 kg exenatide
vs.−0.89 kgsitagliptin;treatmentdifference:−0.48,p<0.05).
Safety
The most common adverse events were nausea (exenatide
39%; sitagliptin 15%), vomiting (exenatide 19%; sitagliptin
5%), headache (exenatide 14%; sitagliptin 14%) and diarrhoea
(exenatide 10%; sitagliptin 10%). Two subjects experienced
serious adverse events (SAEs) while on exenatide (confusional
state and anaphylactic reaction). Neither SAE was assessed to
be related to the study drug. In the opinion of the investigator,
neither event was related to exenatide treatment. No subject
discontinued the study due to an adverse event. Three subjects
on exenatide and one subject on sitagliptin experienced minor
hypoglycaemia.Therewasnoepisodeofmajorhypoglycaemia.
Discussion
Several glucoregulatory mechanisms showed key differences
between exenatide and sitagliptin in lowering blood glucose
levels. Our study showed signiﬁcant decreases in the average
daily glucose, glucagon concentrations, caloric intake and
improved β-cell function with exenatide treatment. The
predominant glucodynamic difference between exenatide and
sitagliptin in the current study was the observation that
exenatide substantially decreased PPG concentration, with no
signiﬁcantdifferenceonfastingglucosebetweenthetwodrugs.
This observation can be explained at least in part by multiple
mechanisms, the most important of which may be glucagon
suppression [15]. The current study showed that exenatide
had a more pronounced effect on glucagon suppression
than sitagliptin, which had a modest effect on glucagon.
Greater glucagon suppression with exenatide compared to
sitagliptin is consistent with a previous study [10]. Shah
et al. demonstrated that lack of glucagon suppression can
cause substantial hyperglycaemia when insulin availability is
limited [15].Cerveraet al.showedthatsuppressionofglucagon
secretion and stimulation of insulin secretion by exenatide
each accounted for approximately one-third of the decline in
glucose concentrations following a meal, while the remainder
ofglucosesuppressionwasbecauseofdelayedgastricemptying
and increased splanchnic glucose uptake [16]. Thus, decreased
PPG concentrations can be mediated, at least in part, by
exenatide’s greater effect on gastric emptying compared with
sitagliptin [10]. Using acetaminophen absorption, DeFronzo
et al. demonstrated signiﬁcantly slower gastric emptying with
exenatide than sitagliptin [10]. In the current study, subjects
receiving exenatide consumed signiﬁcantly fewer calories over
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Table 2. Baseline, endpoint and change in the metabolic parameters, β-cell function and blood pressure.
Exenatide Sitagliptin
LS mean
(s.e.m.) p-value∗ 95% CI
LS mean
(s.e.m.) p-value∗ 95% CI p-value†
24-h Averaged glucose
(mmol/l)
<0.001 <0.001 <0.001
Baseline 9.7 (0.3) 9.7 (0.3)
Endpoint 7.4 (0.1) 8.1 (0.1)
Change −2.3 (0.1) −2.6 to 2.0 −1.6 (0.1) −1.9 to −1.4
2-h PPG (mmol/l) <0.001 <0.001 <0.001
Baseline 12.9 (0.4) 12.9 (0.4)
Endpoint 6.9 (0.2) 10.5 (0.2)
Change −6.0 (0.2) −6.5 to −5.5 −2.5 (0.2) −2.9 to −2.0
Fasting glucose (mmol/l) <0.001 <0.001 0.766
Baseline 9.2 (0.3) 9.2 (0.3)
Endpoint 7.6 (0.1) 7.6 (0.1)
Change −1.6 (0.1) −1.9 to −1.3 −1.6 (0.1) −1.9 to −1.3
Difference between max and
min glucose (mmol/l)
<0.001 <0.001 0.010
Baseline 7.8 (0.2) 7.7 (0.3)
Endpoint 5.5 (0.2) 6.2 (0.2)
Change −2.3 (0.2) −2.7 to −1.9 −1.5 (0.2) −1.9 to −1.1
AUC for glucose >7.8 mmol/l
(mmol/l × h)
<0.001 <0.001 <0.001
Baseline 55.3 (5.6) 55.1 (5.6)
Endpoint 15.8 (2.5) 26.1 (2.5)
Change −39.6 (2.5) −44.6 to −34.6 −29.3 (2.5) −34.3 to −24.3
AUC for glucose >11 mmol/l
(mmol/l × h)
<0.001 <0.001 0.010
Baseline 16.8 (2.9) 16.7 (2.9)
Endpoint 2.3 (1.1) 5.1 (1.1)
Change −14.5 (1.1) −16.7 to −12.4 −11.8 (1.1) −13.9 to −9.6
Time with glucose between
3.9 and 7.8 mmol/l (h)
<0.001 <0.001 <0.001
Baseline 7.4 (0.9) 7.1 (0.8)
Endpoint 15.1 (0.6) 12.4 (0.6)
Change 7.9 (0.6) 6.6–9.1 5.2 (0.6) 4.0–6.5
HOMA-B (%) <0.001 <0.001 0.005
Baseline 53.2 (4.2) 53.8 (4.3)
Endpoint 86.1 (3.8) 74.0 (3.9)
Change 32.9 (3.8) 25.4–40.4 20.8 (3.9) 13.0–28.6
Diastolic BP (mm/Hg) 0.250 0.325 0.112
Baseline 74.8 (1.0) 75.4 (1.1)
Endpoint 76.2 (0.9) 74.2 (0.9)
Change 1.1 (0.9) −0.8 to 2.9 −0.9 (0.9) −2.7 to 0.9
Systolic BP (mm/Hg) 0.106 0.198 0.818
Baseline 124.6 (1.8) 125.4 (1.8)
Endpoint 122.5 (1.5) 123.0 (1.6)
Change −2.5 (1.5) −5.6 to 0.5 −2.0 (1.6) −5.1 to 1.1
AUC,areaunderthecurve;BP,bloodpressure;CI,conﬁdenceinterval;HOMA-B,homeostasismodelassessmentofβ-cellfunction;LSMean,least-squares
mean; max, maximum; min, minimum; PPG, postprandial glucose; s.e.m., standard error of the mean.
∗Change from baseline.
†Between-treatment comparison.
a24-hperiodcomparedtositagliptin.Thisﬁndingisconsistent
with that of DeFronzo et al. in which decreased caloric intake
was observed with exenatide compared to sitagliptin during a
test meal in a subset of patients [10]. The difference in caloric
intake occurred at the midday meal, with the exenatide group
consuming signiﬁcantly fewer calories than the sitagliptin
group. One might have expected this difference to occur at
the standardized breakfast meal or at the dinner meal because
the injections were given then. However, the difference in
caloriesbetweengroupsatthemiddaymealcouldbeattributed
todelayedgastricemptyingandsatietyoccurringpostbreakfast
whenpatientsreceivedexenatidebeforethebreakfasttestmeal.
Although we measured weight in the current study and a
statistical difference was observed between groups, the study
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Figure 3. Glucose (A), insulin (B), intact GLP-1 (C) and glucagon (D) concentrations before and after individualized morning meal at baseline and
endpoint. ∗p < 0.005 change from baseline, #p < 0.005 between-group comparison. GLP-1, glucagon-like peptide-1.
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Figure 4. Metabolic parameters by sequence. (A) 24-h averaged glucose
by treatment sequence at baseline, 4 weeks (end of treatment period 1)
and 8 weeks (end of treatment period 2). (B) 2-h postprandial glucose by
treatment sequence at baseline, 4 weeks (end of treatment period 1) and 8
weeks (end of treatment period 2).
design and short duration preclude the ability to make clinical
inferences.
Exenatide has been reported to improve measures of
β-cell function in type 2 diabetes [17,18]. In the current
study, exenatide had a greater effect on β-cell function than
sitagliptin,asmeasuredbyHOMA-B(consistentwithDefronzo
et al. [10]). Decreased postprandial insulin concentrations in
the current study during exenatide treatment compared to
sitagliptin are consistent with other studies [18] and reﬂect
improved β-cell function relative to the improved PPG
concentrations.
A recent open-label study by Arnolds et al. showed no
difference in PPG excursions over 6 h between exenatide and
sitagliptin when either drug was added to treatment for 48
subjects with type 2 diabetes receiving insulin glargine [19].
However,severalstudydifferencesexistbetweenourstudy and
that of Arnolds et al. We examined glucose over an entire 24-h
period in the absence of insulin glargine. In Arnolds et al.,
the power to detect differences was much lower compared to
our study, given only 15 and 16 completers in the exenatide
and sitagliptin arms, respectively, and the parallel design of
thatstudy.Furthermore,Arnoldset al.reportedfastingglucose
concentrations well below those typically reported in clinical
trials in which glargine was uptitrated [20–22]. The current
study may be more typical of patients with type 2 diabetes in
clinical practice.
The current study conﬁrms previous observations that
sitagliptin increases endogenous intact GLP-1 in subjects
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with type 2 diabetes [23]. In contrast, exenatide decreased
postprandial intact GLP-1 concentrations. To our knowledge,
this study is the ﬁrst to report an apparent suppression of
postprandial GLP-1 concentrations during treatment with
exenatide. Such a reduction could be explained by a negative
feedback mechanism whereby exenatide inhibited further
GLP-1 release from L-cells. Flint et al. demonstrated that an
intravenous infusion of GLP-1 suppressed GLP-2, which is
also secreted by the L-cells [24]. Defronzo et al. showed that
the molar concentrations of exenatide exceed those of GLP-1
during treatment with sitagliptin [10], which may account for
thegreatereffectofexenatideonpostprandialand24-hglucose
concentrations.
A limitation of this study is the lack of a washout period
between the two treatments. However, the short half-lives of
sitagliptin and exenatide (12 and 2.4 h, respectively) make
a carryover effect unlikely [2,3]. Furthermore, the treatment
difference in period 1 was greater than in period 2, so in the
presenceofacarryovereffect,thetreatmentdifferenceestimate
would be biased towards showing no difference. Residual
biologic activity of either drug cannot be ruled out. Strengths
of this study include its double-dummy, double-blinded,
crossover design in which all completing subjects received
both drugs, with the subjects each receiving two injections and
one capsule each day. This design limited potential study bias.
In conclusion, the 24-h glucose proﬁles obtained during
treatment with either exenatide or sitagliptin revealed that the
predominant difference between the drugs lies in the ability
of exenatide to substantially decrease PPG concentration.
The effect of exenatide to improve 24-h glucose proﬁle
relative to sitagliptin may be explained, at least in part, by
agreatereffectofexenatideonsuppressingPPGconcentration,
decreased appetite, decreased caloric intake, and improved
insulin response to the ambient glucose. The overall effects of
exenatide in the current study may be because of a greater
molar concentration of exenatide compared to the molar
concentration of intact GLP-1 during sitagliptin therapy [10].
Acknowledgements
We would like to thank Dr Sherwyn Schwartz, Dr Douglas
Denham,LisaHolland,RN,andtheresearchstaffattheCetero
Research Corporation for conducting this study; Ying Evelyn
Guo, MS and Yongming Qu, PhD, for statistical support;
Steven Brock Findlay for project management; Michelle Lewis,
PhD, for comments on study design; Byron J. Hoogwerf,
MD, and Mark Hartman, MD, for their critical review of
the manuscript; and Barbara McLean and Casey Brackney for
editorial assistance.
Conﬂict of Interest
Dr Berg was the principal investigator for this trial and is
employed by the Cetero Research which provides contract
services for Eli Lilly and Company. Drs Holcombe, Heilmann,
Shenouda and Alison Gray are employees of Lilly USA, LLC.
No other potential conﬂicts of interest relevant to this article
were reported.
All authors had full access to the data, participated in every
aspect of data analysis and manuscript development and gave
ﬁnal approval of the manuscript. J. K. B. made ﬁnal decisions
on manuscript content. S. K. S. wrote the manuscript and
researched data. C. R. H. researched data, wrote statistical
methods and reviewed manuscript. A. L. G. contributed to
the protocol design and reviewed/edited the manuscript. J. H.
H. contributed to the protocol design and discussion, and
reviewed and edited the manuscript.
References
1. Drucker DJ.Thebiologyofincretinhormones.CellMetab2006;3:153–165.
2. Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and phar-
macodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in
healthy subjects: results from two randomized, double-blind, placebo-
controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78:
675–688.
3. Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exe-
natide) signiﬁcantly reduces postprandial and fasting plasma glucose
in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88:
3082–3089.
4. Degn KB, Brock B, Juhl CB et al. Effect of intravenous infusion of exenatide
(synthetic exendin-4) on glucose-dependent insulin secretion and
counterregulation during hypoglycemia. Diabetes 2004; 53: 2397–2403.
5. Edwards CM, Stanley SA, Davis R et al. Exendin-4 reduces fasting and
postprandial glucose and decreases energy intake in healthy volunteers.
Am J Physiol Endocrinol Metab 2001; 281: E155–161.
6. Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynam-
ics, and safety of exenatide in patients with type 2 diabetes mellitus. Am
J Health Syst Pharm 2005; 62: 173–181.
7. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of
exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism
2001; 50: 583–589.
8. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-
Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as
monotherapy on glycemic control in patients with type 2 diabetes.
Diabetes Care 2006; 29: 2632–2637.
9. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efﬁcacy and safety of
thedipeptidylpeptidase-4inhibitorsitagliptinaddedtoongoingmetformin
therapy in patients with type 2 diabetes inadequately controlled with
metformin alone. Diabetes Care 2006; 29: 2638–2643.
10. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, Mac-
Conell L. Effects of exenatide versus sitagliptin on postprandial glucose,
insulin and glucagon secretion, gastric emptying, and caloric intake: a
randomized, cross-over study. Curr Med Res Opin 2008; 24: 2943–2952.
11. World Medical Association Declaration of Helsinki. Recommendations
guiding physicians in biomedical research involving human subjects. JAMA
1997; 277: 925–926.
12. Schwartz SL, Ratner RE, Kim DD et al. Effect of exenatide on 24-hour blood
glucose proﬁle compared with placebo in patients with type 2 diabetes:
a randomized, double-blind, two-arm, parallel-group, placebo-controlled,
2-week study. Clin Ther 2008; 30: 858–867.
13. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling.
Diabetes Care 2004; 27: 1487–1495.
14. Grizzle JE. The two-period change-over design an its use in clinical trials.
Biometrics 1965; 21: 467–480.
15. Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon
on glucose tolerance in humans. Am J Physiol Endocrinol Metab 1999;
277: E283–290.
988 Berg et al. Volume 13 No. 11 November 2011DIABETES, OBESITY AND METABOLISM original article
16. Cervera A, Wajcberg E, Sriwijitkamol A et al. Mechanism of action of
exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
Am J Physiol Endocrinol Metab 2008; 294: E846–E852.
17. Bunck MC, Diamant M, Corner A et al. One-year treatment with exenatide
improves β-cell function, compared with insulin glargine, in metformin-
treated type 2 diabetic patients: a randomized, controlled trial. Diabetes
Care 2009; 32: 762–768.
18. DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC. Effects of
exenatide plus rosiglitazone on β cell function and insulin sensitivity
in subjects with type 2 diabetes on metformin. Diabetes Care 2010;
951–957.
19. Arnolds S, Dellweg S, Clair J et al. Further improvement in postprandial
glucose control with the addition exenatide or sitagliptin to combination
therapy with insulin glargine and metformin: a proof-of-concept study.
Diabetes Care 2010; 33: 1509–1515.
20. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement
of glycemic control in subjects with poorly controlled type 2 diabetes:
comparison of two treatment algorithms using insulin glargine. Diabetes
Care 2005; 28: 1282–1288.
21. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2
diabetes: a comparison of biphasic and basal insulin analogs. Diabetes
Care 2005; 28: 260–265.
22. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized
addition of glargine or human NPH insulin to oral therapy of type 2
diabetic patients. Diabetes Care 2003; 26: 3080–3086.
23. Herman GA, Bergman A, Stevens C et al. Effect of single oral doses of
sitagliptin, a dipeptidyl peptidase-4 Inhibitor, on incretin and plasma
glucose levels after an oral glucose tolerance test in patients with type 2
diabetes. J Clin Endocrinol Metab 2006; 91: 4612–4619.
24. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological
levels of glucagon-like peptide-1 on appetite, gastric emptying, energy
and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001;
25: 781–792.
Volume 13 No. 11 November 2011 doi:10.1111/j.1463-1326.2011.01428.x 989